These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


592 related items for PubMed ID: 12474228

  • 1. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
    Koesters R, Niggli F, von Knebel Doeberitz M, Stallmach T.
    J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
    [Abstract] [Full Text] [Related]

  • 2. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
    Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K, Reeve AE.
    Pediatr Dev Pathol; 2004 Jan; 7(2):125-37. PubMed ID: 14994125
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Significance of aberrant (cytoplasmic/nuclear) expression of beta-catenin in pancreatoblastoma.
    Tanaka Y, Kato K, Notohara K, Nakatani Y, Miyake T, Ijiri R, Nishimata S, Ishida Y, Kigasawa H, Ohama Y, Tsukayama C, Kobayashi Y, Horie H.
    J Pathol; 2003 Feb; 199(2):185-90. PubMed ID: 12533831
    [Abstract] [Full Text] [Related]

  • 6. Beta-catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E-cadherin and accumulation of p53, but not with expression of conventional WNT-1 target genes.
    Prange W, Breuhahn K, Fischer F, Zilkens C, Pietsch T, Petmecky K, Eilers R, Dienes HP, Schirmacher P.
    J Pathol; 2003 Oct; 201(2):250-9. PubMed ID: 14517842
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
    Demunter A, Libbrecht L, Degreef H, De Wolf-Peeters C, van den Oord JJ.
    Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
    [Abstract] [Full Text] [Related]

  • 9. Chibby, a novel antagonist of the Wnt pathway, is not involved in Wilms tumor development.
    Zirn B, Wittmann S, Graf N, Gessler M.
    Cancer Lett; 2005 Mar 18; 220(1):115-20. PubMed ID: 15737694
    [Abstract] [Full Text] [Related]

  • 10. Expression and localization of HGF and met in Wilms' tumours.
    Alami J, Williams BR, Yeger H.
    J Pathol; 2002 Jan 18; 196(1):76-84. PubMed ID: 11748645
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix.
    Shinohara A, Yokoyama Y, Wan X, Takahashi Y, Mori Y, Takami T, Shimokawa K, Tamaya T.
    Gynecol Oncol; 2001 Sep 18; 82(3):450-5. PubMed ID: 11520139
    [Abstract] [Full Text] [Related]

  • 16. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
    Pritchard-Jones K, Fleming S.
    Oncogene; 1991 Dec 18; 6(12):2211-20. PubMed ID: 1722569
    [Abstract] [Full Text] [Related]

  • 17. Canonical WNT signalling determines lineage specificity in Wilms tumour.
    Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE.
    Oncogene; 2009 Feb 26; 28(8):1063-75. PubMed ID: 19137020
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
    Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA.
    Oncogene; 2000 Jan 27; 19(4):498-504. PubMed ID: 10698519
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 30.